TrianglePUBLICATIONS · 25204639
Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Cancer
- Publication date
- 2015 Jan 15
- First author
- Chen YB
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Chen YB
- type
- Author
- name
- Batchelor T
- type
- Author
- name
- Li S
- type
- Author
- name
- Hochberg E
- type
- Author
- name
- Brezina M
- type
- Author
- name
- Jones S
- type
- Author
- name
- Del Rio C
- type
- Author
- name
- Curtis M
- type
- Author
- name
- Ballen KK
- type
- Author
- name
- Barnes J
- type
- Author
- name
- Chi AS
- type
- Author
- name
- Dietrich J
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Chen YB
- type
- Author
- name
- Batchelor T
- type
- Author
- name
- Li S
- type
- Author
- name
- Hochberg E
- type
- Author
- name
- Brezina M
- type
- Author
- name
- Jones S
- type
- Author
- name
- Del Rio C
- type
- Author
- name
- Curtis M
- type
- Author
- name
- Ballen KK
- type
- Author
- name
- Barnes J
- type
- Author
- name
- Chi AS
- type
- Author
- name
- Dietrich J
- type
- Author
- bibliography ids
- nci-bib-70a793447f0ec2f43ce6a64b
- book metadata
- content sha256
- ca0910f14282a48195d5694c499aa3a9a5cf3c931472868958ae193afb701981
- document type
- citation
- dois
- 10.1002/cncr.29023
- electronic publication date
- display
- 2014 Sep 9
- precision
- day
- year
- 2014
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:25204639
- immutable id
- pubmed:25204639@ca0910f14282a48195d5694c499aa3a9a5cf3c931472868958ae193afb701981
- journal
- abbreviation
- Cancer
- issn electronic
- 1097-0142
- issn print
- 0008-543X
- issue
- 2
- name
- Cancer
- nlm unique id
- 0374236
- pages
- 226-33
- volume
- 121
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 25204639
- provenance
- batch id
- 69903be8ceab8801c81a
- provider
- NCBI PubMed ESummary
- record sha256
- 127b15861f35b232998ead15c99f1a4713ebb9a0b7cb1d889f47e267c7ace41e
- response sha256
- 1e367491c3c459a93f45b3db99ca1f9293ed2287c48bdf758bb088ffcd7c96eb
- retrieved at
- 2026-09-09T23:47:05.208886+00:00
- publication date
- display
- 2015 Jan 15
- precision
- day
- year
- 2015
- publication types
- Clinical Trial, Phase II
- Journal Article
- Multicenter Study
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.
Preserved source evidence · Not medical advice